News | December 06, 2013

Three-Year Results From SYMPLICITY HTN-2 Shows Significant and Sustained Drops in Blood Pressure Renal Denervation

Longest-term data from the first randomized, controlled trial of renal denervation presented at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium

December 6, 2013 – Medtronic, Inc. presented three-year data from SYMPLICITY HTN-2, the first and longest-running randomized, controlled clinical trial of renal denervation, which continue to demonstrate results consistent with data reported previously at six, 12 and 24-months of follow-up. The data were presented for the first time during an oral abstract session on Tuesday, October 29, 2013 at the 25th Annual Transcatheter Cardiovascular Therapeutics (TCT) Symposium taking place this week in San Francisco. The Symplicity renal denervation system is available for investigational use only in the United States.

“As the first and longest-term experience in a randomized, controlled setting, these data mark a significant milestone for the renal denervation clinical community, as well as the single-electrode Symplicity system,” said Robert J. Whitbourn, M.B.B.S., M.D., associate professor and director of the Cardiovascular Research Centre at St. Vincent’s Hospital in Melbourne. “These results continue to demonstrate the impact renal denervation can have on patients with uncontrolled hypertension, and these data are an important contribution to the growing body of evidence supporting renal denervation with the Symplicity system as a therapy option for this underserved population.”

The data show an average blood pressure reduction of -33/-14 mm Hg [p<0.01] from baseline and an overall response rate (systolic blood pressure drop of greater than or equal to 10 mm Hg) of 85 percent for patients initially randomized to treatment with the Symplicity system and available for 36-month evaluation (n=40). Despite a mean systolic blood pressure of 183.5 ± 19.5 mm Hg pre-denervation, 50 percent of these patients achieved the goal of systolic blood pressure of <140 mm Hg. The safety profile of renal denervation with the Symplicity system was also maintained at three years, with no newly reported device or procedure related serious adverse events. None of the patients treated with the Symplicity system followed through three years required renal artery stenting.

In this trial, patients were required to have severe, uncontrolled hypertension with a systolic blood pressure greater than or equal to 160 mm Hg despite the use of three or more antihypertensive medications, including a diuretic. All patients were maintained on their usual antihypertensive medications and were randomly allocated in a one-to-one ratio to undergo renal denervation or no additional treatment (control group). At baseline, the randomized treatment and control patients had similar high blood pressures: 178/97 mm Hg and 178/98 mm Hg, respectively, despite both receiving an average daily regimen of five antihypertensive medications. Patients in the control arm of the study were offered renal denervation following assessment of the trial’s primary endpoint at six months following randomization. This crossover treatment group experienced significant and sustained blood pressure reductions at 30 months after renal denervation with an average blood pressure reduction of –33/-13 mm Hg [p<0.01] from baseline (n=30).

The complete data was presented by Robert J. Whitbourn, M.B.B.S., M.D., during an oral abstract session titled Renal Denervation and Endovascular Intervention.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init